Patients receiving post-transplant cyclophosphamide to prevent graft-versus-host disease have lower risk for bronchiolitis obliterans syndrome.

Allogene Therapeutics (NASDAQ:ALLO) detailed interim results from its pivotal Phase II ALPHA3 study during a business update ...

SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...

The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...

European Commission grants conditional marketing authorisation to Sanofi’s Rezurock to treat chronic graft-vs-host disease: Paris Wednesday, April 1, 2026, 11:00 Hrs [IST] The E ...

An international task force of medical experts recently proposed major revisions to the way doctors measure treatment success for a common–and often severe–skin complication of stem cell ...

Please provide your email address to receive an email when new articles are posted on . Over 65% of patient-reported treatment responses agreed with clinicians’ evaluations, whereas 34.4% did not.